JP2018519296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519296A5 JP2018519296A5 JP2017566323A JP2017566323A JP2018519296A5 JP 2018519296 A5 JP2018519296 A5 JP 2018519296A5 JP 2017566323 A JP2017566323 A JP 2017566323A JP 2017566323 A JP2017566323 A JP 2017566323A JP 2018519296 A5 JP2018519296 A5 JP 2018519296A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- protein
- unit
- polypeptide
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/064070 WO2015197598A2 (en) | 2014-06-27 | 2015-06-23 | Multispecific antigen binding proteins |
| EPPCT/EP2015/064070 | 2015-06-23 | ||
| US201562271491P | 2015-12-28 | 2015-12-28 | |
| US62/271,491 | 2015-12-28 | ||
| PCT/EP2016/064528 WO2016207273A2 (en) | 2015-06-23 | 2016-06-23 | Multispecific antigen binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519296A JP2018519296A (ja) | 2018-07-19 |
| JP2018519296A5 true JP2018519296A5 (OSRAM) | 2019-06-27 |
| JP6840682B2 JP6840682B2 (ja) | 2021-03-10 |
Family
ID=57584754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566323A Active JP6840682B2 (ja) | 2015-06-23 | 2016-06-23 | 多重特異的抗原結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200048345A1 (OSRAM) |
| EP (1) | EP3313876B1 (OSRAM) |
| JP (1) | JP6840682B2 (OSRAM) |
| AU (1) | AU2016284866B2 (OSRAM) |
| CA (1) | CA2990511A1 (OSRAM) |
| DK (1) | DK3313876T3 (OSRAM) |
| WO (1) | WO2016207273A2 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519234B2 (en) | 2014-06-27 | 2019-12-31 | Innate Pharma | NKp46 binding proteins |
| DK3160994T3 (da) | 2014-06-27 | 2025-05-05 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| CA2990518A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CN117510643A (zh) * | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| CN110913902A (zh) * | 2017-02-10 | 2020-03-24 | 蜻蜓疗法股份有限公司 | 结合psma、nkg2d和cd16的蛋白质 |
| EP3583133A4 (en) * | 2017-02-20 | 2021-04-14 | Dragonfly Therapeutics, Inc. | GD2, NKG2D AND CD16 BINDING PROTEINS |
| ES2955074T3 (es) * | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| JP2020510646A (ja) * | 2017-02-20 | 2020-04-09 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| KR20200130514A (ko) * | 2017-02-27 | 2020-11-18 | 드래곤플라이 쎄라퓨틱스, 인크. | Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질 |
| WO2018217945A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| WO2018217947A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| CA3064743A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and ror1 or ror2 |
| IL271818B2 (en) * | 2017-07-21 | 2024-10-01 | Trianni Inc | Single chain vh and heavy chain antibodies |
| MX2020002036A (es) * | 2017-08-23 | 2020-03-24 | Dragonfly Therapeutics Inc | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. |
| EP3713959A1 (en) * | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| US20210238290A1 (en) * | 2018-05-07 | 2021-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and p-cadherin |
| BR112020023299A2 (pt) * | 2018-05-16 | 2021-02-02 | Dragonfly Therapeutics, Inc. | proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos |
| AU2019272575A1 (en) | 2018-05-21 | 2020-12-10 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by NK cells |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CA3187272A1 (en) * | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| EP4271709A1 (en) | 2020-12-31 | 2023-11-08 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US20240199750A1 (en) | 2021-03-26 | 2024-06-20 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| KR20240019297A (ko) * | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
| WO2022258678A1 (en) * | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN113838523A (zh) * | 2021-09-17 | 2021-12-24 | 深圳太力生物技术有限责任公司 | 一种抗体蛋白cdr区域氨基酸序列预测方法及系统 |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| JP2025532464A (ja) * | 2022-09-15 | 2025-10-01 | アビディキュア アイピー ビー．ブイ． | Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| US20050260213A1 (en) | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| DE20308171U1 (de) | 2003-05-21 | 2003-07-31 | Aesculap AG & Co. KG, 78532 Tuttlingen | Wirbelkörperersatzimplantat |
| US7825085B2 (en) * | 2003-06-30 | 2010-11-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| PL1919503T3 (pl) | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス，インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| BRPI1014089A2 (pt) * | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
| DK2560683T4 (da) * | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| WO2012088302A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| CA2881765C (en) | 2012-09-19 | 2024-02-13 | Innate Pharma | Kir3dl2 binding agents |
| WO2014100490A1 (en) * | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| US10519234B2 (en) * | 2014-06-27 | 2019-12-31 | Innate Pharma | NKp46 binding proteins |
| CA2990518A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| EP4271709A1 (en) * | 2020-12-31 | 2023-11-08 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
-
2016
- 2016-06-23 US US15/738,506 patent/US20200048345A1/en not_active Abandoned
- 2016-06-23 EP EP16733394.7A patent/EP3313876B1/en active Active
- 2016-06-23 AU AU2016284866A patent/AU2016284866B2/en active Active
- 2016-06-23 CA CA2990511A patent/CA2990511A1/en active Pending
- 2016-06-23 DK DK16733394.7T patent/DK3313876T3/da active
- 2016-06-23 JP JP2017566323A patent/JP6840682B2/ja active Active
- 2016-06-23 WO PCT/EP2016/064528 patent/WO2016207273A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519296A5 (OSRAM) | ||
| JP2018524326A5 (OSRAM) | ||
| US11180553B2 (en) | Chimeric antigen receptor | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| RU2753882C2 (ru) | Трифункциональная антигенсвязывающая молекула | |
| JP2024037778A (ja) | 生物学的に関連する直交サイトカイン／受容体対 | |
| JP2016516049A5 (OSRAM) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| RU2022102624A (ru) | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков | |
| JP7303391B2 (ja) | バイアス型ｉｌ２ムテイン、方法、および組成物 | |
| JP2019528077A5 (OSRAM) | ||
| KR20200052373A (ko) | 키메라 폴리펩티드 및 그의 용도 | |
| JP2022542543A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| JP2019531725A5 (OSRAM) | ||
| JP2015527070A5 (OSRAM) | ||
| JP2017538401A5 (OSRAM) | ||
| JP2020529835A (ja) | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 | |
| KR20180057720A (ko) | 다가 Fv 항체 | |
| JPWO2020047473A5 (OSRAM) | ||
| CN107405398A (zh) | 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途 | |
| JP2016525551A5 (OSRAM) | ||
| JP2015518479A5 (OSRAM) | ||
| JP2020512820A5 (OSRAM) |